At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, ...

The benchmarking report used a rigorous methodology to ensure results reflected ICON’s true impact and performance in the competitive phase 1 landscape. ISR screened participants to ensure relevance ...

ICON lifts its 2025 revenue forecast, beats booking targets in Q2 and expands its share buyback plan as market conditions ...

This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer .

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharma innovator, today announced its engagement with ICON Clinical Research Limited ("ICON") to expand it's Phase II Clinical Trial for ...

Additional clinical sites in the EU will assess HT-001 for the treatment of skin toxicities associated with EGFRi.

ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured in the first half of 2025 with a number of business awards, recognising the ...

Thirty patients are being recruited to take part in a study looking at the potentially cancer-killing abilities of dandelion root extract, taken from the common yellow yard weed.